c-Aminobutyric acid (GABA A ) receptors are thought to play an important role in modulating the central nervous system in response to stress. Animal data have shown alterations in the GABA A receptor complex by uncontrollable stressors. SPECT imaging with benzodiazepine ligands showed lower distribution volumes of the benzodiazepine-GABA A receptor in the prefrontal cortex of patients with post-traumatic stress disorder (PTSD) in one, but not in another study. The objective of the present study was to assess differences in the benzodiazepine-GABA A receptor complex in veterans with and without PTSD using [ 11 C]flumazenil and positron emission tomography (PET). Nine drug naive male Dutch veterans with deployment related PTSD and seven male Dutch veterans without PTSD were recruited, and matched for age, region and year of deployment. Each subject received a [
Introduction
Anxiety disorders are associated with alterations in a number of neuroendocrine and neurotransmission systems, including the hypothalamic-pituitary-adrenal axis, and serotonin, noradrenalin, and g-aminobutyric acid (GABA) systems. GABA is the principal inhibitory neurotransmitter in the brain, exerting control over excitability in most brain areas. GABA plays an important role in homeostasis during stress and alterations in GABAergic systems have been implicated in the pathogenesis of anxiety disorders, including posttraumatic stress disorder (PTSD) and depression. Low plasma GABA levels after a traumatic event are predictive of subsequent development of PTSD, 1 suggesting that the GABA system is involved in the pathophysiology of PTSD. Involvement of the GABA system in PTSD has been examined using a variety of different paradigms, including preclinical studies, pharmacologic studies and neuroimaging techniques.
In the stress-restress paradigm, an animal model that shows resemblance to PTSD, stress evoked a sustained decrease in hippocampal GABA levels. 2 Exposure of rodents to inescapable foot shock, a model for stress-related depression characterized by deficits in learning and memory, resulted in decreased GABA A function and binding in the cerebral cortex and hippocampus. [3] [4] [5] Benzodiazepines, which modulate the GABA A receptor function, inhibit the startle response induced by predator stress. 6 These predator stress paradigms model aspects of hyperarousal seen in patients with PTSD.
Pharmacological studies have also provided support for the involvement of the GABA system in PTSD. Benzodiazepines have fast-acting anxiety reducing properties, which have led to their widespread use as treatment for anxiety disorders, including PTSD. Although benzodiazepines are effective in reducing anxiety in PTSD, they have no effect on the core symptoms of this disorder, such as intrusive thoughts, numbing and hyperarousal. [7] [8] [9] A putative role of GABA in PTSD is also supported by treatment studies with other GABAergic compounds, such as tiagabine, a selective GABA reuptake inhibitor. 10, 11 Neuroimaging techniques provide a unique opportunity to investigate receptor binding and neurotransmitter release in vivo. Only a few neuroimaging studies of the benzodiazepine-GABA A receptor in PTSD have been performed and all these studies used single photon emission computed tomography (SPECT) and [
123 I]iomazenil. Using this technique, it has been reported that Vietnam veterans with PTSD had lower volumes of distribution of [ 123 I]iomazenil in the prefrontal cortex (Brodmann's area 9) when compared to healthy controls. 12 A more recent [ 123 I]iomazenil SPECT study, however, was unable to confirm these results in Gulf War veterans compared to undeployed military controls. 13 Positron emission tomography (PET) using [ 11 C]flumazenil is a more accurate technique for quantifying benzodiazepine-GABA A receptor binding than SPECT imaging using [ 123 I]iomazenil. Apart from being fully quantitative, PET also has superior spatial resolution compared to SPECT. PET imaging using [ 11 C]flumazenil has been employed frequently in patients with epilepsy [14] [15] [16] and in patients with schizophrenia.
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PET is also an important neuroimaging tool used in studies of psychiatric drug action and in novel drug development. 18 To the best of our knowledge, the present study is the first to investigate GABAergic functioning in PTSD using PET and [
11 C]flumazenil. Based on preclinical studies and clinical findings, the working hypothesis of the present study was that veterans with PTSD have reduced [ 11 C]flumazenilbinding potential in both cortical areas and the hippocampus compared to veterans without PTSD.
Materials and methods

Subjects
Nine male Dutch veterans with PTSD (patient group) and seven male Dutch veterans without PTSD (control group) were recruited for this study. Veterans with PTSD were recruited from the Department of Military Psychiatry at the Central Military Hospital in Utrecht. Control veterans were recruited via direct mail to veterans who were registered at the Veterans Institute in The Netherlands. All veterans had served in UN peacekeeping missions in Lebanon and Bosnia. Control veterans were matched to the patient group with respect to age, year of deployment and country of deployment. None of the veterans included was physically injured during the time of deployment. At study entry, all veterans were medication naive (that is, they had never used psychotropic medication). In addition, none of the veterans had a history of benzodiazepine usage or alcohol abuse within 6 months before the study. Urinary drug screening was performed in all veterans on the morning of the day on which the PET scan was performed. None of the veterans needed to be excluded from the study because of benzodiazepine or other drug use. In addition, veterans were excluded when they had a history of neurological illness or psychiatric illness other than mood or anxiety disorders. In addition, for all veterans, no clinically significant abnormalities were visible on the MRI scan (as determined by a neuroradiologist). Finally, control veterans had to fulfil Research Diagnostic Criteria for never being mentally ill.
All veterans were evaluated with the Structured Clinical Interview for DSM-IV (SCID; 19 ClinicianAdministered PTSD Scale for DSM-IV) CAPS; 20 Hamilton Depression Scale (HAM-D), and Hamilton Anxiety Scale (HAM-A). In veterans with PTSD, PTSD was the primary diagnosis. PTSD was confirmed by the CAPS and through consensus by three clinicians (EG, EV, CdK). Control veterans without PTSD also met the A1 criterion for PTSD (that is, they had also experienced traumatic events). Control veterans were only included if their CAPS score was less than 20. Written informed consent was obtained from all veterans after a complete written and verbal description of the study. A total of nine veterans with PTSD and seven veterans without PTSD were included. The 21, 22 All subjects received an indwelling radial artery cannula for arterial blood sampling and a venous cannula for tracer injection.
First, a 10 min transmission scan was performed in 2D acquisition mode using three retractable rotating line sources. This scan was used to correct the subsequent emission scan for photon attenuation. Then a dynamic emission scan in 3D acquisition mode was started simultaneously with the intravenous injection of 371756 MBq (mean7s.d.) of [ 11 C]flumazenil using an infusion pump at 0.8 ml/s, after which the line was flushed with 42 ml saline at 2.0 ml/s (Med-Rad, Beek, The Netherlands). The specific activity (SA) was 0.03070.011 MBq/nM (mean7s.d.). The estimated receptor binding associated with these high specific activity tracer doses is < 1%. This dynamic emission scan consisted of 16 frames with progressive increase in frame duration (4 Â 15, 4 Â 60, 2 Â 150, 2 Â 300, 4 Â 600 s) and a total duration of 60 min. Arterial blood was withdrawn continuously at a rate of 5 ml/min for the first 10 min and 2.5 ml/min thereafter, using an online detection system (Veenstra Instruments, Joure, The Netherlands), which was cross-calibrated against the PET scanner. 23 At 2.5, 5, 10, 20, 30, 40, and 60 min postinjection, continuous withdrawal was briefly interrupted for manual collection of blood samples. These samples were used to measure both whole blood and plasma concentrations. In addition, the plasma samples were used to determine parent [
11 C]flumazenil fractions. Motion of the subject in the PET camera was checked visually at regular intervals (by checking the position of the head with laser beams).
Image reconstruction
All PET sinograms were corrected for dead time, tissue attenuation using the transmission scan, decay, scatter and randoms, and reconstructed using a standard filtered backprojection algorithm and a Hanning filter with cutoff at 0.5 times the Nyquist frequency. A zoom factor of 2 and a matrix size of 256 Â 256 Â 63 were used, resulting in a voxel size of 1.2 Â 1.2 Â 2.4 mm and a spatial resolution of approximately 7 mm full-width at half-maximum at the centre of the field of view. Images were then transferred to workstations (Sun Microsystems, Santa Clara, CA, USA) for further analysis.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) of all subjects was performed at the Department of Radiology of the University Medical Centre of Utrecht. MRI scans were acquired using a 1.5T scanner (Philips Gyroscan; Philips Medical Systems, Best, The Netherlands). These scans were used for segmentation of grey and white matter and for delineation of regions of interest (ROI). T1-weighted, 3D, fast-field echo scans with 160-180 1.2 mm contiguous coronal slices (echo time, 4.6 ms; repetition time, 30 ms; flip angle 301; field of view 256 mm) of the whole head were used for coregistration with PET.
Region of interest definition MRI images were aligned to corresponding PET images using a mutual information algorithm included in MIRIT (multimodality image registration using information theory 24, 25 ). The data were analysed using a probability-map-based automatic delineation of 35 ROIs that delineates the whole brain (bilateral areas were counted as one ROI). 26 This method is a fast, objective, reproducible, and safe way to assess regional brain values from PET or SPECT scans, which has previously been described and validated. 26 The 35 ROIs are based on manual definition of these ROIs in MRI images of 10 healthy controls. Each ROI represents the volume that is present in each individual ROI after warping to a standard brain. Using a warping algorithm, template ROI sets defined from each individual were transferred to the MR images of the individual new subject. The voxels overlapping after these individual warpings are used as the final ROI. ROIs in this template include the bilateral cerebellum, bilateral orbital frontal cortex, bilateral medial inferior frontal cortex, bilateral anterior cingulate cortex, bilateral insula, bilateral thalamus, bilateral caudate nuclei, bilateral putamen, bilateral superior temporal cortex, bilateral parietal cortex, bilateral medial inferior temporal cortex, bilateral superior frontal cortex, bilateral occipital cortex, bilateral sensory motor cortex, bilateral posterior cingulate cortex, bilateral enthorinal cortex, bilateral striatum, and midbrain. In addition to this template, manual ROIs for bilateral hippocampi, bilateral amygdala, and pons were defined on the fused MRI scan using DISPLAY (http://www.bic. mni.mcgill.ca/) according to standard anatomical criteria.
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Kinetic analysis
Kinetic analyses were performed using dedicated software developed within Matlab 5.3 (The Mathworks, Natick, MA, USA). Manual samples collected during scanning were used to calibrate the online blood curve, to determine plasma to whole blood ratios of radioactivity, and to measure plasma metabolite fractions. Metabolite fractions were determined using HPLC, as described previously. 29 The online blood curve was calibrated using the manual whole blood samples. Plasma to whole blood ratios were fitted to an exponential function and multiplied with the whole blood (online sampler) curve to obtain the corresponding (total) plasma curve. Finally, this plasma curve was multiplied with the parent fraction using a Hill function to obtain a metabolite-corrected plasma input function. [ 11 C]flumazenil time-activity curves were generated by projecting all ROIs onto all frames of the dynamic [
11 C]flumazenil scan. Metabolite-corrected plasma input curves were available for seven patients and seven controls due to technical reasons. These data were analysed using a single tissue compartment model yielding the outcome parameter volume of distribution (V d ). This was used to confirm the use of the pons as reference tissue. The single tissue compartment includes free, non-specific and specific compartments, and assumes that all tissue pools equilibrate rapidly with respect to bloodbrain barrier transport rates. 30 Data from all nine patients and seven controls were then analysed using the simplified reference tissue model (SRTM) resulting in the outcome parameter binding potential 31 (BP). The use of the SRTM (with pons as reference tissue) for quantification of [
11 C]flumazenil BP has recently been validated. 32 Owing to the small sample size and because data were not normally distributed, the Mann-Whitney U-test was used for all ROI data. All statistical analyses were performed with SPSS 12.0 for Windows (SPSS, Chicago, IL, USA). The statistical threshold for significance for all measures was set at P < 0.05.
SPM analysis
In addition to above ROI analysis, a voxel-by-voxel SPM analysis was performed. This analysis was to assess whether there were clusters of voxels with altered binding not identified in the ROI analysis, for example due to heterogeneity within an ROI. Before SPM analysis, scans were checked visually for motion artefacts. Motion was checked by overlaying the outline contour of the patient's head on each frame of the dynamic study allowing assessment of interframe displacements. None of the scans needed to be excluded. For the SPM analysis, BP images were generated using Ichise plots of dynamic data from 10 to 60 min post injection. 33 Before Ichise plot analysis, dynamic scans were smoothed using an additional 10 mm full-width half-maximum Gaussian filter to reduce noise, thereby avoiding noise induced bias during Ichise analysis. As the cortical distribution of [ 11 C]flumazenil is similar to that of water, normalization was performed using the standard water template included within SPM. Correct normalization was checked visually by direct comparison of normalized BP images and the template used. Next, these plots were used in a voxel-based comparison between the two groups using SPM2 (http://www.fil.ion.ucl. ac.uk/spm). As images were already smoothed before Ichise analysis, the usual smoothing within SPM was omitted. SPM was performed without proportional scaling. Proportional scaling may be omitted because, following smoothing, Ichise plots are quantitatively accurate even at lower noise levels. The images were thresholded at P < 0.001, uncorrected for multiple comparisons, using a cluster size k > 50 voxels. 34 In addition, the false discovery rate was used to provide corrected P-values.
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Results
Psychometric data
Veterans with PTSD had significantly greater CAPS, Hamilton A, and Hamilton D scores (Table 1) . According to the SCID, the PTSD group met lifetime (past) DSM-IV (American Psychiatric Association 1994) diagnostic criteria for the following disorders: major depressive disorder (n = 4), bipolar disorder (n = 1), alcohol abuse (n = 2), manic episode (n = 1), and panic disorder with agoraphobia (n = 1). Only one veteran with PTSD met current diagnostic criteria for panic disorder with agoraphobia. The two veterans with PTSD who had formerly been diagnosed with alcohol abuse were abstinent for a period greater than 6 months. Among the control subjects, the SCID did not reveal any psychiatric disorders.
ROI analysis
There was no statistically significant difference between the volume of distribution of [ (Figure 1 and Table 3 ). SPM and ROI analyses showed nearly similar results. In both analyses, decreased [ 11 C]flumazenil binding in veterans with PTSD was found throughout cortical and subcortical areas. However, SPM analysis did not show significant differences in the left striatum and the left amygdala.
Discussion
To the best of our knowledge, this is the first fully quantitative PET study demonstrating reduced bind- Benzodiazepine binding sites in the brain are located predominantly on the GABA A receptors, and therefore their distribution in the brain reflects the distribution of GABA A receptors. Benzodiazepines potentiate the function of GABA through conformational changes in the receptor, thereby increasing the effectiveness of GABA for opening the ion channel. Animal models support the notion that stress and trauma can alter GABA A -benzodiazepine binding density. 2, 6, [36] [37] [38] In general, these animal models have shown decreased GABA A function and binding in the cerebral cortex and hippocampus. [3] [4] [5] This is the first benzodiazepine-GABA A receptor binding study in patients with PTSD that supports these preclinical data.
The present finding of reduced [ 11 C]flumazenil binding throughout most of the cortical areas may be indicative of an a priori difference in subunit composition of GABA A -benzodiazepine receptors, a lower expression of the GABA A receptor in PTSD patients, or a disease or trauma-induced modulation or downregulation of the GABA A receptor complex. These explanations are consistent with other clinical studies that have suggested altered GABAergic function in PTSD. 1, 7, 10 A reduced GABAergic function can also be explained by the presence of increased levels of GABA.
Since the control subjects in this study had also experienced traumatic events, the observed difference in [ 11 C]flumazenil binding in this study is disorder related and not due to trauma. However, this does not preclude the possibility that stress or trauma, in trauma-exposed individuals who do not develop PTSD, can alter GABA function. In the absence of a healthy control group of subjects who have never experienced psychological trauma, it cannot be determined whether the observed difference in binding between veterans with and without PTSD is unique to PTSD or represents a quantitative difference in binding density.
Decreased binding to benzodiazepine-GABA A receptors is consistent with an [
123 I]iomazenil SPECT study in Vietnam veterans with PTSD. 12 In that study, Vietnam veterans with PTSD had a decreased volume of distribution (V d ) of [
123 I]iomazenil in the prefrontal cortex (one of the two a priori defined regions) compared to age-matched healthy controls. Another [ 123 I]iomazenil SPECT study in Gulf War veterans with PTSD, however, was unable to find any significant differences in V d of [ 123 I]iomazenil compared to age-matched undeployed military personnel. 13 Possible factors that could account for the discrepancy in findings of these studies are, as mentioned by Fujita et al., 13 related to type of controls Table 3. used and the interval between traumatic experiences and the study. In the study by Bremner et al.
12 healthy subjects were used as controls, and the interval was about 25 years. In the second study by Fujita et al., 13 controls included were military personnel who had served at the same time, but who were not deployed. In addition, the interval between deployment and time of study was about 10 years. These differences, however, cannot explain differences in findings with the present study, where control subjects were veterans who were matched to the patient group, and who had been deployed to the same countries at the same time as the veterans with PTSD. In addition, in the present study the interval between traumatic experiences and the PET study was also about 10-12 years.
SPECT is a semi-quantitative method that requires global normalization before SPM analysis. This may also explain why the SPECT studies performed in PTSD 12, 13 did not report a global reduction in V d of [ 123 I]iomazenil in PTSD. Any potential global differences would have been removed by the global normalization. Interestingly, in panic disorder, which is related to PTSD a global reduction of [
11 C]flumazenil binding was also found throughout the brain, 39 suggesting that the GABAergic system is indeed involved in these anxiety disorders.
Several studies have shown that the prefrontal cortex is dysfunctional in PTSD. [40] [41] [42] [43] [44] Across these studies, however, dysfunctional alterations occurred in different parts of the prefrontal cortex, indicating that failure of prefrontal inhibition in PTSD needs to be clarified in the future. In the present study, a reduction of GABA A -benzodiazepine BP throughout the frontal cortex was found. This may underlie the working memory deficit in patients with PTSD. 45 Decreases in GABA A receptor binding are also associated with alterations in working memory performance. 37, 38 In addition, appropriate GABA neurotransmission in the frontal cortex is required for a normal working memory function. 46 Another important brain area is the hippocampus, which plays a pivotal role in managing the stress response, novelty detection and memory processing. The hippocampus is also an important site for GABA and serotonin interaction, which is thought to modulate emotional behaviour. 47 In patients with PTSD structural and functional alterations of the hippocampus have consistently been demonstrated. [48] [49] [50] [51] Benzodiazepine agonists enhance GABA A C]flumazenil-binding potential compared to control veterans without PTSD. Talairach coordinates, corrected P-values (false discovery rate-corrected P = 0.003) and the Z-score of peak voxels are reported. BAs corresponding to the Talairach coordinates of the peak voxel are also reported.
Reduced binding to benzodiazepine receptor E Geuze et al receptor function in the CA1 region of the hippocampus and can thus disrupt memory formation and hippocampal synaptic plasticity. 52 It is also possible that in patients with PTSD increased sensitivity to stress causes the alterations in GABA A receptors. In a previous SPECT study, patients with panic disorder also revealed decreased GABA A -benzodiazepine receptor binding in the left hippocampus. 53 Other brain areas, which play an important role in anxiety disorders, such as the left amygdala and the left caudate nucleus, also showed a reduction in benzodiazepine receptor binding. Several neuroimaging studies in PTSD have revealed that the amygdala plays an important role in the modulation of emotional responses in PTSD. [54] [55] [56] In addition, the amygdala also seems to play a role in nociceptive responses in veterans with PTSD. 57 The caudate nucleus has been implicated in a number of anxiety disorders, including obsessive compulsive disorder and social phobia. In relation to PTSD, the caudate nucleus has attracted little attention from neurobiological research. It seems, however, that caudate function should also be examined in future PTSD studies. Certainly, the relation of the dopaminergic system (hence also the caudate nucleus) to PTSD should be examined in more detail, considering the recent use of atypical antipsychotics as pharmacotherapy in PTSD. 58, 59 All research methods employed have both methodological advantages and limitations. In the present study, SRTM with pons as reference tissue was used for analyzing the data. Apart from enabling inclusion of data from all subjects (due to technical reasons the arterial plasma curve could not be used in two subjects), an important advantage of this method is that it measures binding potential for specific binding only. In contrast, the generally accepted single tissue compartment model with plasma input (requiring arterial cannulation) measures the volume of distribution of total binding (that is, both specific and nonspecific binding). Reference tissue models such as SRTM require more assumptions than plasma input models, but they exhibit less variance in determining specific binding making them more reproducible. 60 Recently, the use of SRTM with pons as reference tissue in the quantification of [ 11 C]flumazenil PET has been validated in a large sample of normal controls and patients with depression. 32 This validation supports the plausibility of the present results, as data were analysed in a similar manner. Although head motion was visually checked during scanning and a visual check for motion artefacts before analyses of the scans was performed, no additional motion correction was applied before SPM and ROI analysis. Watabe et al. 61 have proposed an elegant method for motion correction during a dynamic PET scan. However, this implies acquisition of the data in listmode, which is not commercially available on HR þ scanners. As such, data were acquired in the standard frame-mode, making motion correction with this method impossible.
Other potential confounders of the present study are related to sample size and study population. Like in most PET studies the number of subjects included was relatively small. As a result, ROI data were not normally distributed, requiring nonparametric methods of analysis. Therefore, care should be taken in generalizing the present results. One of the main strengths of this study is the use of matched trauma controls. Therefore, the results are likely to be related to the effect of PTSD itself, and not the effect of having witnessed traumatic events or the stress of deployment. With two matched groups, one with PTSD and one without, the question may arise why some subjects develop PTSD, while others do not. Therefore, it would be interesting for future research to investigate the effects of personality differences and genetic makeup on neurobiological differences in PTSD. As this study only included male veterans with PTSD, care should be taken in extrapolating these findings to females with PTSD, and to PTSD related to other types of trauma. Therefore, further studies are warranted. Future research should also consider whether the observed effects are basal or adaptive changes, as the present study cannot distinguish between predisposing, mediating, or resultant factors.
In conclusion, this study has shown decreased [ 11 C]flumazenil binding throughout the brain of veterans with PTSD compared to veterans without PTSD. This provides support for the involvement of GABA A benzodiazepine receptors in PTSD and warrants further investigation of GABAergic functioning in PTSD.
